ePrints

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Lookup NU author(s): Professor Fai NgORCiD

Downloads

• Accepted version [.pdf]

Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by Elsevier, 2020.

For re-use rights please refer to the publisher's terms and conditions.

Publication metadata

Author(s): Fisher BA, Szanto A, Ng WF, Bombardieri M, Posch MG, Papas AS, Farag AM, Daikeler T, Bannert B, Kyburz D, Kivitz AJ, Carsons SE, Isenberg DA, Barone F, Bowman SJ, Espie P, Floch D, Dupuy C, Ren X, Faerber PM, Wright AM, Hockey HU, Rotte M, Milojevic J, Avrameas A, Valentin MA, Rush JS, Gergely P

Publication type: Article

Publication status: Published

Journal: The Lancet Rheumatology

Year: 2020

Volume: 2

Issue: 3

Pages: e142-e152

Print publication date: 01/03/2020

Online publication date: 23/01/2020

Acceptance date: 23/01/2020

Date deposited: 15/06/2020

ISSN (electronic): 2665-9913

Publisher: Elsevier

URL: https://doi.org/10.1016/S2665-9913(19)30135-3

DOI: 10.1016/S2665-9913(19)30135-3

Altmetrics

Share